Objective To discuss the effects of Liuwei Dihuang Decoction on expressions of TGF-β1 and complement regulatory protein CR1 of the renal on IgA nephropathy rats.Methods Forty SD rats were randomized into normal group, model group, tripterygium glycosides group and Liuwei Dihuang Decoction group after adaptive feeding for one week. Complex method was used to establish IgA nephropathy model. All administration groups were given relevant medicine for gavage for 4 weeks;urine routine, the number of urine erythrocyte and 24 h urine protein were detected;creatinine, urea nitrogen, total serum protein and serum alburin were detected from blood;the renal pathological changes were observed under light microscope by HE and Masson staining;the expressions of TGF-β1 and CR1 were detected by immunohistochemistry.Results Compared with model group,Liuwei Dihuang Decoction could significantly decrease the proteinuria and hematuria levels and renal fibrosis changes of IgA nephropathy model rats, reduce the expression of TGF-β1, and raise the expression of CR1 (P<0.05).Conclusion Liuwei Dihuang Decoction can delay the renal fibrosis in IgA nephropathy rats through reducing the degree of TGF-β1 and promoting the expression of CR1.

AIM: To evaluate the clinical effect of Iron Dextran Dispersible Tablets on patients with chronic heart failure who reduced ejection fraction after 24 weeks. METHODS: From January 2020 to June 2022, forty-five patients with heart failure complicated with iron deficiency and reduced ejection fraction were selected as the research objects. According to the random number table, they were randomly divided into control group and observation group.The control group was given routine anti-heart failure treatment such as Sacubitril Calsartan sodium tablets, while the observation group was given iron dextran dispersible tablets 50 mg three times a day on the basis of the anti-heart failure treatment of the control group for 8 weeks. The 6-minute walking distance, Hemoglobin, Serum Ferritin, N-terminal B-type natriuretic peptide precursor, Left Ventricular Ejection Fraction, Left Ventricular end Diastolic Diameter and 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score and clinical summary score were compared between the two groups. RESULTS: There was no significant difference in baseline data between the two groups (P > 0.05). After treatment, the 6-minute walking distance in the observation group was longer than that in the control group, while the serum ferritin level in the observation group was higher than that in the control group. The N-terminal pro-B-type natriuretic peptide level in the two groups was lower than that before treatment, and the left ventricular end diastolic diameter was shorter than that before treatment, and the left ventricular ejection fraction, clinical comprehensive score and symptom score were higher than that before treatment. The difference was statistically significant (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05). CONCLUSION: Iron Dextran Dispersible Tablets can improve the exercise endurance and quality of life of patients with chronic heart failure who reduced ejection fraction after 24 weeks.